Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 7 , ISSUE 1 ( January-June, 2017 ) > List of Articles


Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals

Sameh M Abdel Monem

Citation Information : Abdel Monem SM. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepatogastroenterol 2017; 7 (1):101-106.

DOI: 10.5005/jp-journals-10018-1226

License: CC BY 3.0

Published Online: 01-04-2018

Copyright Statement:  Copyright © 2017; The Author(s).



Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world. A subgroup of NAFLD patients is characterized by injury to the hepatocytes and inflammation in addition to excessive fat (steatohepatitis), the latter condition is nominated nonalcoholic steatohepatitis (NASH). This work aimed to evaluate the role of probiotics on the outcome of NASH in patients admitted to the Tropical Medicine Department, Faculty of Medicine, Zagazig University (inpatients and outpatients).

Materials and methods

This study was performed on 30 patients (17 males and 13 females), with body mass index from 30 to 35 and average age of 44 years with bright fatty liver in ultrasonography and raised alanine transaminase (ALT) and aspartate transaminase (AST) and positive liver biopsy findings. The patients were divided into group I (case group) that included 15 patients who received probiotics and group II of 15 patients as control group who did not receive probiotics; the study was conducted between November 2014 and April 2016. Clinical assessment, laboratory evaluation, pelvic-abdominal ultrasound, and liver biopsy of all cases were carried out.


In this study, there was significant decrease in liver enzymes (ALT and AST) and no statistically significant other laboratory findings. Also there was relief for dyspepsia in some patients.


Probiotics treatment is effective, safe, well-tolerated, inexpensive, appropriate for long-term use, and optimally, works at multiple levels to downregulate inflammatory mediators, and therefore, probiotics could be an option in the treatment of NASH.

How to cite this article

Monem SMA. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepato-Gastroenterol 2017;7(1):101-106.

  1. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010 May;26(3):202-208.
  2. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012 Sep;56(3):933-942.
  3. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002 Dec;17 Suppl 3:S377-S384.
  4. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002 Jul;123(1):134-140.
  5. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004 Aug;27(8):2057-2066.
  6. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999 Nov;107(5):450-455.
  7. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002 Apr;35(4):746-752.
  8. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000 Nov;343(20):1467-1476.
  9. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002 Feb;122(2):274-280.
  10. Endotoxin and alcoholic liver disease: tolerance and susceptibility. Hepatology 1999 May;29(5):1602-1604.
  11. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995 Jan;108(1):218-224.
  12. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994 Mar;205(3):243-247.
  13. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000 Feb;130(2S Suppl):396S-402S.
  14. Does probiotics administration decrease serum endotoxin levels in infants? J Pediatr Surg 1999 Feb;34(2):273-276.
  15. ; Clark, M. Clinical medicine (textbook). 5th ed. Edinburgh: WB Saunders; 2002. p. 1092-1098.
  16. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003 May;98(5):960-967.
  17. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995 Nov;127(5):700-704.
  18. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007 Mar;23(2):193-198.
  19. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995 Sep;40(9):2002-2009.
  20. Non-alcoholic Fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003 May;38(5):681-687.
  21. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005 Jul;39(6):540-543.
  22. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006;13(24):2889-2900.
  23. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013 Mar-Apr;12(2):256-262.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.